Open access · CC-BY
via OpenAlex
Peptide-based approaches to directly target alpha-synuclein in Parkinson’s disease
Scott G. Allen, Richard M. Meade, Lucy L. White Stenner, Jody M. Mason
Molecular Neurodegeneration · 2023 · ▲ 35 citations
Abstract
Peptides and their mimetics are increasingly recognised as drug-like molecules, particularly for intracellular protein-protein interactions too large for inhibition by small molecules, and inaccessible to larger biologics. In the past two decades, evidence associating the misfolding and aggregation of alpha-synuclein strongly implicates this protein in disease onset and progression of Parkinson's disease and related synucleinopathies. The subsequent formation of toxic, intracellular, Lewy body deposits, in which alpha-synuclein is a major component, is a key diagnostic hallmark of the disease. To reach their therapeutic site of action, peptides must both cross the blood-brain barrier and enter dopaminergic neurons to prevent the formation of these intracellular inclusions. In this review, we describe and summarise the current efforts made in the development of peptides and their mimetics to directly engage with alpha-synuclein with the intention of modulating aggregation, and importantly, toxicity. This is a rapidly expanding field with great socioeconomic impact; these molecules harbour significant promise as therapeutics, or as early biomarkers during prodromal disease stages, or both. As these are age-dependent conditions, an increasing global life expectancy means disease prevalence is rising. No current treatments exist to either prevent or slow disease progression. It is therefore crucial that drugs are developed for these conditions before health care and social care capacities become overrun.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1186/s13024-023-00675-8
- Canonical
- link ↗
- Fetched
- 2026-10-21 MST
Cite this
APA
Allen, S.G., Meade, R.M., Stenner, L.L.W., & Mason, J.M. (2023). Peptide-based approaches to directly target alpha-synuclein in Parkinson’s disease. <em>Molecular Neurodegeneration</em>. https://doi.org/10.1186/s13024-023-00675-8
Vancouver
Allen SG, Meade RM, Stenner LLW, Mason JM. Peptide-based approaches to directly target alpha-synuclein in Parkinson’s disease. Molecular Neurodegeneration. 2023. doi:10.1186/s13024-023-00675-8.
BibTeX
@article{scott2023Peptid,
title = {Peptide-based approaches to directly target alpha-synuclein in Parkinson’s disease},
author = {Scott G. Allen and Richard M. Meade and Lucy L. White Stenner and Jody M. Mason},
journal = {Molecular Neurodegeneration},
year = {2023},
doi = {10.1186/s13024-023-00675-8},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Aging Neuroscience 2020
Open access · CC-BY
Protein-Protein Interactions in Alpha-Synuclein Biogenesis: New Potential Targets in Parkinson’s Disease
Neurobiology of Disease 2024
Open access · CC-BY
Interactions of alpha-synuclein with membranes in Parkinson's disease: Mechanisms and therapeutic strategies
npj Parkinson s Disease 2022
Open access · CC-BY
Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies
Age and Ageing 2010
Citation only
Ageing, neurodegeneration and Parkinson's disease
Aging advances. 2026
Open access · CC-BY
Age-related synaptic vesicle dysfunction as a prodromal target in Parkinson’s disease: Mechanistic insights from alpha-synuclein biology
Cells 2022
Open access · CC-BY